Molecular Partners Ag - American Depositary Shares (MOLN) closed at $3.56 on October 16, 2026, down 5.1% from the previous close, on volume of 680 shares (30-day average 1,503).
Data as of October 16, 2026.
No headlines found.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
Molecular Partners Ag - American Depositary Shares trades on the NASDAQ stock market under the symbol MOLN.
As of October 16, 2026, MOLN stock price declined to $3.56 with 680 million shares trading.
MOLN has a market cap of $133.14 million. This is considered a Micro Cap stock.
In the last 3 years, MOLN traded as high as $12.70 and as low as $3.32.
MOLN has underperformed the market in the last year with a price return of -7.5% while the SPY ETF gained +16.7%. MOLN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.2% and -11.7%, respectively, while the SPY returned +1.9% and -0.8%, respectively.
MOLN support price is $3.52 and resistance is $3.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MOLN shares will trade within this expected range on the day.
